

Albuterol Inhaler Recall Alert

Date of Notice: 09/21/2020

Brief Description of Recall Alert

The U.S. Food and Drug Administration (FDA) is alerting health care professionals and patients of a voluntary recall of all unexpired albuterol sulfate inhalers manufactured by Catalent Pharma Solutions for Perrigo Pharmaceutical Company in Minneapolis, due to possible clogging of the inhaler resulting in patients not receiving enough or any drug. The FDA urges patients to continue using the inhaler they have on hand.

Affected Products

Drug Name & Strength	NDC	Lot	Expiration Date
albuterol sulfate inhaler	45802-0088-01	All lots	All dates

Prescriber Information

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail, or by fax.

- Complete and submit the report <u>Online</u>
- Regular Mail or Fax: <u>Download form</u> or call 1-800-332-1088 to request a reporting form, then complete and return to the address on the pre-addressed form, or submit by fax to 1-800-FDA-0178

Member Information

The albuterol inhaler delivers the drug into the body through the airway and lungs, where it opens the airways to treat asthma and other conditions, such as chronic obstructive pulmonary disease (COPD). Patients could face health risks if their rescue albuterol inhaler malfunctions and does not relieve symptoms in an emergency situation. FDA advises patients to:

- immediately seek emergency care if needed;
- use their Perrigo inhaler they have on hand, as needed and as directed by a doctor;
- have extra inhalers or an alternative treatment available in case of malfunction, as some of these recalled inhalers stop working after several uses; and
- contact their health care professional or pharmacist with questions.

RxAdvance Response

RxAdvance is in the process of contacting members and prescribers to advise them of this recall.

This document is designed to be an informational resource to facilitate discussion and should be used neither as a basis for clinical decision-making or treatment nor as a substitute for reading original literature. RxAdvance makes every effort to ensure that the information provided is up-to-date, accurate, and complete, but no guarantee is made to that effect. If this information is provided to clients or vendors, it is subject to any contractual confidentiality provisions. Third-party disclosures are in violation of confidentiality provisions.

© 2020 RxAdvance Corporation. Confidential and Proprietary.

Page 1 of 1 v 2.7.04.1